AnaptysBio Inc reports results for the quarter ended June 30 - Earnings Summary

AnaptysBio

06/08/2025 22:05

AnaptysBio Inc ANAB.OQ reported a quarterly adjusted loss of $1.34​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $-1.71.  The mean expectation of eleven analysts for the quarter was for a loss of $1.54 per share. Wall Street expected results to range from $-1.85 to -89 cents per share.

Revenue rose 102.9% to $22.26 million from a year ago; analysts expected $11.55 million.

AnaptysBio Inc's reported EPS for the quarter was a loss of $1.34​.

AnaptysBio Inc shares had risen by 6.7% this quarter and gained 78.9% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had fallen by about 2.7% in the last three months.​

In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for AnaptysBio Inc is $45.50, about 47.9% above its last closing price of $23.69

This summary was machine generated from LSEG data August 6 at 09:04 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Jun. 30 2025
-1.54
-1.34
Beat
Mar. 31 2025
-1.25
-1.28
Missed
Dec. 31 2024
-1.62
-0.72
Beat
Sep. 30 2024
-1.65
-1.14
Beat